Zoetis Inc. (NYSE:ZTS) Stake Decreased by Outlook Wealth Advisors LLC

Outlook Wealth Advisors LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 3,218 shares of the company’s stock after selling 66 shares during the quarter. Outlook Wealth Advisors LLC’s holdings in Zoetis were worth $629,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Prevail Innovative Wealth Advisors LLC raised its holdings in shares of Zoetis by 24.5% during the first quarter. Prevail Innovative Wealth Advisors LLC now owns 18,977 shares of the company’s stock valued at $3,211,000 after buying an additional 3,738 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its stake in shares of Zoetis by 58.6% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 41,931 shares of the company’s stock valued at $7,095,000 after acquiring an additional 15,491 shares during the period. Duality Advisers LP increased its stake in shares of Zoetis by 43.7% during the first quarter. Duality Advisers LP now owns 40,641 shares of the company’s stock valued at $6,877,000 after acquiring an additional 12,359 shares during the period. M&G Plc acquired a new position in shares of Zoetis during the first quarter valued at approximately $19,819,000. Finally, Cetera Investment Advisers increased its stake in shares of Zoetis by 275.2% during the first quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock valued at $16,259,000 after acquiring an additional 70,476 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $180.01 on Friday. The company’s fifty day moving average is $189.18 and its two-hundred day moving average is $177.61. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a market cap of $82.14 billion, a P/E ratio of 34.68, a price-to-earnings-growth ratio of 2.94 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the previous year, the business earned $1.41 EPS. The company’s revenue was up 8.3% on a year-over-year basis. Equities analysts expect that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.96%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 33.14%.

Analyst Ratings Changes

A number of research analysts recently commented on ZTS shares. Piper Sandler raised their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus raised their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.